Yuen Man-Fung, Sablon Erwin, Yuan He-Jun, Wong Danny Ka-Ho, Hui Chee-Kin, Wong Benjamin Chun-Yu, Chan Annie On-On, Lai Ching Lung
Division of Gastroenterology and Hepatology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Hepatology. 2003 Mar;37(3):562-7. doi: 10.1053/jhep.2003.50098.
The pathologic role of hepatitis B virus (HBV) genotype in Chinese patients with HBV infection is largely unknown. We examined the relationship between HBV genotypes, and hepatitis B e antigen (HBeAg) seroconversion, acute exacerbation, cirrhosis-related complications, and precore/core promoter mutations. Three hundred forty-three HBV patients (288 were asymptomatic, 55 presented with cirrhosis-related complications) were recruited. HBV genotypes and precore/core promoter mutations were determined by line probe assays. Genotypes B and C were the 2 most common genotypes, contributing 28% and 60%, respectively. The median age of HBeAg seroconversion for patients with genotype B was 9 years earlier than patients with genotype C (P =.011). There were no differences in the liver biochemistry, HBV DNA level, and cumulative risk of acute exacerbation (defined as increased alanine aminotransferase level > or =1.5 x upper limit of normal) between patients with genotypes B and C. There was a trend for patients with genotype B to have a higher cumulative rate of HBeAg seroconversion compared with patients with genotype C at the initial follow-up of 6 years (P =.053), but this difference became insignificant during subsequent follow-up. The prevalence of both genotypes was the same in patients with and without cirrhosis-related complications and/or hepatocellular carcinoma. Genotype B was associated with precore mutations (P <.0001), whereas genotype C was associated with core promoter mutations (P <.0001). In conclusion, although patients with genotype B had earlier HBeAg seroconversion, there was no significant reduction in the risk of development of complications. Genotypes B and C are associated with high prevalence of precore and core promoter mutations, respectively.
乙肝病毒(HBV)基因型在中国HBV感染患者中的病理作用很大程度上尚不清楚。我们研究了HBV基因型与乙肝e抗原(HBeAg)血清学转换、急性加重、肝硬化相关并发症及前C区/核心启动子突变之间的关系。招募了343例HBV患者(288例无症状,55例出现肝硬化相关并发症)。通过线性探针分析确定HBV基因型和前C区/核心启动子突变。B型和C型是最常见的两种基因型,分别占28%和60%。B型基因型患者HBeAg血清学转换的中位年龄比C型基因型患者早9年(P = 0.011)。B型和C型基因型患者在肝生化指标、HBV DNA水平及急性加重的累积风险(定义为丙氨酸氨基转移酶水平升高>或=正常上限的1.5倍)方面无差异。在最初6年的随访中,B型基因型患者的HBeAg血清学转换累积率有高于C型基因型患者的趋势(P = 0.053),但在随后的随访中这种差异变得不显著。有和没有肝硬化相关并发症和/或肝细胞癌的患者中,两种基因型的患病率相同。B型基因型与前C区突变相关(P < 0.0001),而C型基因型与核心启动子突变相关(P < 0.0001)。总之,尽管B型基因型患者HBeAg血清学转换较早,但并发症发生风险并无显著降低。B型和C型基因型分别与前C区和核心启动子突变的高患病率相关。